What is Omega Bio-tek?
Established in 1998, Omega Bio-tek has cemented its reputation as a critical provider of nucleic acid isolation technologies. The company maintains an ISO 9001:1998 certification, reflecting its commitment to rigorous quality standards in the development of silica membrane, magnetic bead, and salting-out extraction methods. With a comprehensive portfolio exceeding 900 distinct products, the firm serves a diverse clientele spanning clinical diagnostics, basic research, and agricultural biotechnology. Its dual focus on manual and automated processing solutions allows it to address the evolving needs of high-throughput laboratories and specialized research facilities alike.
How much funding has Omega Bio-tek raised?
Omega Bio-tek has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Omega Bio-tek
PPP
Public-Private Partnership
What's next for Omega Bio-tek?
With the recent infusion of capital, Omega Bio-tek is poised to scale its manufacturing infrastructure and enhance its R&D pipeline for next-generation genomic tools. The strategic focus will likely shift toward optimizing automated workflows, which are increasingly vital for clinical and agricultural sectors requiring high-precision molecular data. As the company navigates this late-stage growth phase, the integration of advanced extraction technologies will be paramount in maintaining its competitive edge against larger industry incumbents. Future initiatives will likely prioritize market penetration in emerging biotech hubs, ensuring that their proprietary isolation kits remain the standard for both academic and commercial research applications.
See full Omega Bio-tek company page
